EquityZen Growth Technology Fund LLC - Series 2011
Raised
$200K
Investors
17
Min Invest
$5,225
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2011 is a Delaware pooled investment fund that raised $200K from 17 investors under Rule 506(b) and Section 3(c)(1) exemptions, with a $5K minimum investment. Filed April 11, 2025 by EquityZen Advisors and Phil Haslett, this entity is part of the EquityZen platform, which operates 1,889 related EDGAR entities focused on pre-IPO access.
This pre-IPO fund vehicle uses the standard 506(b)/3(c)(1) exemption structure common to private secondary market platforms, with a $5K minimum investment typical for retail-accessible alternative investment offerings. The modest raise size and series-based structure align with single-company SPV patterns in the pre-IPO secondary space.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
